PETALING JAYA: Duopharma Biotech Bhd
is expected to see a record profit for this year, underpinned by a stronger ringgit, higher sales and improved operating efficiency.
TA Research said it expects the pharmaceutical group’s earnings to grow by 43.1% to RM88.4mil in 2025. The research house projects Duopharma to register a quarterly profit of between RM12mil and RM15mil in its upcoming results for the fourth quarter of 2024 (4Q24).
